Financial toxicity in a phase I/II trial of LV20.19 CAR-T cell for B-cell malignancies a longitudinal, qualitative study
{{output}}
Background: Financial toxicity, the economic burden associated with cancer treatment, is an evolving concern for patients undergoing innovative therapies like chimeric antigen receptor T-cell (CAR T-cell) therapy. The high costs ... ...
